We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib

This study is not yet open for participant recruitment.
Verified May 2017 by Jeeyun Lee, Samsung Medical Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT03163992
First Posted: May 23, 2017
Last Update Posted: May 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: December 2019
  Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)